Previous close | 57.60 |
Open | 58.06 |
Bid | 54.06 x 100 |
Ask | 54.46 x 200 |
Day's range | 53.59 - 58.42 |
52-week range | 27.02 - 73.00 |
Volume | |
Avg. volume | 347,731 |
Market cap | 2.085B |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.84 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 90.25 |
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...